Transcode Therapeutics, INC. (RNAZ) — 8-K Filings

All 8-K filings from Transcode Therapeutics, INC.. Browse 34 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (34)

Transcode Therapeutics Files 8-K on Agreements and Equity Sales — Apr 7, 2026 Risk: medium
On April 7, 2026, Transcode Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The fi
8-K Filing — Dec 22, 2025
8-K Filing — Dec 11, 2025
Transcode Therapeutics Files 8-K — Oct 27, 2025 Risk: low
Transcode Therapeutics, Inc. filed an 8-K on October 27, 2025, reporting material modifications to the rights of security holders, amendments to its articles of
Transcode Therapeutics Files 8-K — Oct 14, 2025 Risk: low
Transcode Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting an event that occurred on October 13, 2025. The filing is primarily for "Other Events"
Transcode Therapeutics Enters Material Definitive Agreement — Oct 3, 2025 Risk: medium
On September 30, 2025, Transcode Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreeme
Transcode Therapeutics Files 8-K on Shareholder Vote Matters — Sep 2, 2025 Risk: low
Transcode Therapeutics, Inc. filed an 8-K on August 29, 2025, reporting on the submission of matters to a vote of security holders. The filing does not contain
Transcode Therapeutics Files 8-K on Shareholder Nominations — Jun 13, 2025 Risk: medium
Transcode Therapeutics, Inc. filed an 8-K on June 13, 2025, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing date for the repo
Transcode Therapeutics Faces Delisting Concerns — May 7, 2025 Risk: high
Transcode Therapeutics, Inc. filed an 8-K on May 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the e
Transcode Therapeutics Files 8-K on Security Holder Rights — May 5, 2025 Risk: medium
Transcode Therapeutics, Inc. filed an 8-K on May 5, 2025, reporting material modifications to the rights of security holders and amendments to its articles of i
Transcode Therapeutics Files 8-K — May 2, 2025 Risk: low
Transcode Therapeutics, Inc. filed an 8-K on May 2, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial
Transcode Therapeutics Files 8-K — Apr 21, 2025 Risk: low
Transcode Therapeutics, Inc. filed an 8-K on April 21, 2025, reporting on matters submitted to a vote of security holders, other events, and financial statement
Transcode Therapeutics Enters Material Definitive Agreement — Mar 25, 2025 Risk: medium
On March 23, 2025, Transcode Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial stateme
Transcode Therapeutics Files 8-K — Feb 25, 2025 Risk: low
Transcode Therapeutics, Inc. filed an 8-K on February 25, 2025, reporting on the submission of matters to a vote of security holders, other events, and financia
Transcode Therapeutics Files 8-K — Feb 4, 2025 Risk: low
Transcode Therapeutics, Inc. filed an 8-K on February 4, 2025, reporting on matters submitted to a vote of security holders, other events, and financial stateme
Transcode Therapeutics Files 8-K — Dec 20, 2024 Risk: low
Transcode Therapeutics, Inc. filed an 8-K on December 20, 2024, reporting an event that occurred on December 18, 2024. The filing pertains to "Other Events" and
Transcode Therapeutics Files 8-K: Material Agreement & Equity Sales — Dec 2, 2024 Risk: medium
On November 26, 2024, Transcode Therapeutics, Inc. entered into a material definitive agreement, likely related to its business operations. The company also dis
Transcode Therapeutics Files 8-K on Security Holder Rights — Nov 29, 2024 Risk: medium
Transcode Therapeutics, Inc. filed an 8-K on November 29, 2024, reporting a material modification to the rights of security holders and amendments to its articl
Transcode Therapeutics Files 8-K on Shareholder Vote Matters — Nov 25, 2024 Risk: low
Transcode Therapeutics, Inc. filed an 8-K on November 25, 2024, reporting on matters submitted to a vote of security holders as of November 22, 2024. The filing
Transcode Therapeutics Faces Delisting Concerns — Nov 6, 2024 Risk: high
Transcode Therapeutics, Inc. filed an 8-K on November 6, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's pri
Transcode Therapeutics Faces Delisting Concerns — Sep 27, 2024 Risk: high
Transcode Therapeutics, Inc. filed an 8-K on September 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The
Transcode Therapeutics to be Acquired by 03 Life Sciences — Aug 28, 2024 Risk: medium
Transcode Therapeutics, Inc. announced on August 28, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction i
Transcode Therapeutics Faces Delisting Notice — Aug 16, 2024 Risk: high
Transcode Therapeutics, Inc. filed an 8-K on August 16, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The co
Transcode Therapeutics Files 8-K: Material Agreement & Equity Sales — Jul 24, 2024 Risk: medium
Transcode Therapeutics, Inc. announced on July 22, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales o
TransCode Therapeutics Files 8-K on Shareholder Votes — Jun 13, 2024 Risk: low
TransCode Therapeutics, Inc. filed an 8-K on June 13, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specif
Transcode Therapeutics to be Acquired by 03 Life Sciences — Jun 7, 2024 Risk: medium
Transcode Therapeutics, Inc. announced on June 3, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is e
180 Life Sciences to Acquire Transcode Therapeutics — May 15, 2024 Risk: medium
Transcode Therapeutics, Inc. announced on May 15, 2024, that it has entered into a definitive agreement to be acquired by 180 Life Sciences Corp. The transactio
Transcode Therapeutics Faces Listing Rule Issues — May 10, 2024 Risk: high
Transcode Therapeutics, Inc. filed an 8-K on May 10, 2024, reporting a notice of failure to satisfy a continued listing rule or standard. The company's principa
Transcode Therapeutics Files 8-K on Shareholder Nominations — Apr 23, 2024 Risk: medium
Transcode Therapeutics, Inc. filed an 8-K on April 23, 2024, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing date for the rep
Transcode Therapeutics Files 8-K on Financials — Apr 5, 2024 Risk: low
Transcode Therapeutics, Inc. filed an 8-K on April 5, 2024, reporting on its results of operations and financial condition as of April 3, 2024. The filing indic
Transcode Therapeutics Files 8-K for Major Corporate Action — Jan 31, 2024
Transcode Therapeutics, Inc. filed an 8-K on January 31, 2024, reporting an event that occurred on January 26, 2024. The filing indicates that the company is us
RNAZ Raises $4M via Stock Offering & Private Placement — Jan 22, 2024
Transcode Therapeutics, Inc. (RNAZ) entered into a material definitive agreement on January 18, 2024, for a registered direct offering and a concurrent private
Transcode Therapeutics 8-K Hints at Major Governance, Rights Changes — Jan 16, 2024
Transcode Therapeutics, Inc. filed an 8-K on January 16, 2024, reporting events from January 10, 2024. The filing indicates potential material modifications to
RNAZ Files 8-K on Shareholder Vote Submission — Jan 8, 2024
Transcode Therapeutics, Inc. (RNAZ) filed an 8-K on January 8, 2024, indicating a 'Submission of Matters to a Vote of Security Holders.' This filing is a proced

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX